Answers are grounded in this paper and cite their sources.
Objective: This study aimed to investigate the role of LSM12 in uveal melanoma (UM) oncogenesis and progression, examining its potential as both a prognostic biomarker and therapeutic target. Methods: LSM12 expression was analyzed in relation to RNA modification genes and tumor stemness in UM. UM cell lines were subjected to LSM12 knockdown using siRNA, followed by cell viability and migration assays. The therapeutic potential of targeting LSM12 was evaluated using a subcutaneous xenograft model. Additionally, the relationship between LSM12 and the PI3K/Akt/mTOR pathway was explored. Results: LSM12 expression levels were significantly elevated in UM patients, correlating strongly with poor prognosis. Positive correlations were observed between LSM12 expression and multiple genes associated with RNA methylation modifications and cancer stem cell characteristics. Knockdown of LSM12 effectively disrupted UM cell viability and migration in vitro and inhibited OCM1 xenograft growth in vivo. Additionally, LSM12 knockdown resulted in notable inhibition of the PI3K/Akt/mTOR pathway both in vitro and in vivo. Conclusions: Elevated LSM12 expression correlates with poor prognosis in UM and critically promotes oncogenic processes, including tumor cell viability, migration, and tumorigenesis.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: